EGFR and non-small cell lung carcinoma: Data on resistance patterns in the Indian population remains limited.<h4>Materials and methods</h4>This <i>post hoc</i> analysis of a Phase III trial conducted at Tata Memorial Centre (TMC) in Mumbai, India, included 350 patients with advanced EGFR-mutant NSCLC.